search
Back to results

TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy

Primary Purpose

DMD-Associated Dilated Cardiomyopathy

Status
Recruiting
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
talfirastide
Sponsored by
Constant Therapeutics LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for DMD-Associated Dilated Cardiomyopathy

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Male subjects 16 years of age or older who provide informed consent and can follow up with protocol procedures. Parental or guardian consent is required for subjects at least 16 years of age but younger than 18 years of age. Documented diagnosis of Duchenne muscular dystrophy by genetic mutation analysis. Documented cardiomyopathy, as assessed by echocardiogram with EF >35% and <55% and fractional shortening of ≤ 28% at the time of screening. Subjects must be taking systemic glucocorticoids for at least six months prior to screening. Subjects taking mineralocorticoid receptor antagonists, must be taking the drug for at least three months prior to screening Non-ambulant and cared for by a trained caregiver Exclusion Criteria: Therapy with intravenous inotropic or vasoactive medications at the time of screening Planned or likelihood of major surgery in the 6 months after planned enrollment. Patient is using a left ventricular assist device (LVAD) or actively in the process of acquiring a LVAD. Estimated glomerular filtration rate (GFR) <50 mL/min, as calculated by the CKD-EPI Creatinine equation 2021 (https://www.kidney.org/professionals/kdoqi/gfr_calculator) Reproducible (+/- 10%) difference between screening and baseline, percent predicted FVC between 45 and 85, inclusive, using best of 3 efforts at each visit Patients with non-invasive ventilation, such as CPAP and BiPAP Patient is suffering from unstable systemic allergic reaction(s), connective tissue disease or autoimmune disorder(s), requiring active intervention History of cardiac tumor or current cardiac tumor Known moderate-to-severe aortic stenosis/insufficiency or severe mitral stenosis/regurgitation Current alcohol or drug abuse Known history of chronic viral hepatitis unless considered cured based on hepatitis C RNA negative results Hepatic dysfunction upon screening evidenced by bilirubin levels or gamma-GT levels above normal, deemed as clinically significant by the PI/Sub-I, and/or abnormal hematology (hematocrit <25%, WBC <3000/μl, platelets <100,000/μl), without a reversible, identifiable cause. Total bilirubin elevations > 2 times the upper reference range, consistent with Gilbert's Syndrome, may be enrolled if there is no other evidence of liver dysfunction Uncontrolled diabetes (HbA1c >9.0 percent) Inability to comply with protocol-related procedures, including required study visits Any condition or other reason that, in the opinion of the investigator or Medical Monitor, would render the subject unsuitable for the study Currently receiving or received within 90 days of enrollment (Day 1) an investigational treatment on another clinical study or expanded access protocol. This will include patients currently being treated or who have not completed follow-up to treatment with an investigational cell-based therapy within 6 months prior to enrollment and patients actively receiving an investigational therapy for cardiovascular repair/regeneration.

Sites / Locations

  • Hadassah Medical CenterRecruiting
  • Sheba Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TXA127 SC 0.5mg/kg/day

Arm Description

TXA127 (talfirastide) 0.5mg/kg/day given via subcutaneous injection for 6 months

Outcomes

Primary Outcome Measures

To evaluate the safety of TXA127 in patients with DMD
Incidence of adverse events (AEs), their severity and relationship to treatment
To evaluate the effects of treatment on ejection fraction (EF)
Percent change in EF, as measured by echocardiogram (ECHO); Absolute change in EF, as measured by echocardiogram

Secondary Outcome Measures

To evaluate the effects of treatment on upper extremity muscle function
Percent change in upper extremity strength, as measured by grip strength with a dynamometer; Absolute change in upper extremity strength, as measured by grip strength with a dynamometer
To evaluate the effects of treatment on fractional shortening (FS)
Percent and absolute change in fractional shortening as measured by echocardiogram

Full Information

First Posted
August 16, 2023
Last Updated
September 7, 2023
Sponsor
Constant Therapeutics LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT06013839
Brief Title
TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy
Official Title
A Phase 2, Single-Arm, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of TXA127/Angiotensin [1-7] in Non-Ambulant Patients With Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Who Are Receiving Systemic Glucocorticoids
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 31, 2023 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Constant Therapeutics LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
This open-label, single-arm multi-center study studying the safety and efficacy of TXA127 on non-ambulant patients with DMD Cardiomyopathy will comprise of two phases: 6-month open-label treatment phase: Male DMD patients with documented cardiomyopathy, will receive a daily subcutaneous injection of TXA127 0.5 mg/kg. Treatment will be provided for 6 months. Treatment safety will be assessed by collection and review of AEs, vital signs, ECGs, physical examinations, PFTs, and laboratory parameters on Day 1, Month 1, and Month 6. Ejection Fraction, upper extremity strength and biomarker levels will be assessed at these study visits as well. In addition, an abbreviated safety visit will be conducted at Month 3. 12-month optional extension phase: Patients will continue the same study drug regime for an additional 12 months. The primary objective of this phase is to obtain long-term safety data. Efficacy data will also be collected. Safety, efficacy, and exploratory biomarkers will be assessed at Month 12 and Month 18, using the same methods as in the treatment phase. In addition, abbreviated safety visits will be conducted at Month 9 and Month 15.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
DMD-Associated Dilated Cardiomyopathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TXA127 SC 0.5mg/kg/day
Arm Type
Experimental
Arm Description
TXA127 (talfirastide) 0.5mg/kg/day given via subcutaneous injection for 6 months
Intervention Type
Drug
Intervention Name(s)
talfirastide
Other Intervention Name(s)
TXA127, Angiotensin-(1-7)
Intervention Description
TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
Primary Outcome Measure Information:
Title
To evaluate the safety of TXA127 in patients with DMD
Description
Incidence of adverse events (AEs), their severity and relationship to treatment
Time Frame
6 months plus 12 month extension
Title
To evaluate the effects of treatment on ejection fraction (EF)
Description
Percent change in EF, as measured by echocardiogram (ECHO); Absolute change in EF, as measured by echocardiogram
Time Frame
6 months plus 12 month extension
Secondary Outcome Measure Information:
Title
To evaluate the effects of treatment on upper extremity muscle function
Description
Percent change in upper extremity strength, as measured by grip strength with a dynamometer; Absolute change in upper extremity strength, as measured by grip strength with a dynamometer
Time Frame
6 months plus 12 month extension
Title
To evaluate the effects of treatment on fractional shortening (FS)
Description
Percent and absolute change in fractional shortening as measured by echocardiogram
Time Frame
6 months plus 12 month extension
Other Pre-specified Outcome Measures:
Title
To evaluate the effects of treatment on exploratory DMD-related clinical signs, FVC
Description
Forced Vital Capacity (FVC) % predicted Absolute and percent (where applicable) change in the following biomarkers in the blood: Troponin and Brain Natriuretic Peptide (BNP) Brain-derived neurotrophic factor (BDNF)
Time Frame
6 months plus 12 month extension
Title
To evaluate the effects of treatment on exploratory DMD-related clinical signs, PEF
Description
Peak Expiratory Flow (PEF) % predicted (if available) Absolute and percent (where applicable) change in the following biomarkers in the blood: Troponin and Brain Natriuretic Peptide (BNP) Brain-derived neurotrophic factor (BDNF)
Time Frame
6 months plus 12 month extension
Title
To evaluate the effects of treatment on exploratory DMD-related biomarkers, Troponin
Description
Absolute and percent (where applicable) change in Troponin
Time Frame
6 months plus 12 month extension
Title
To evaluate the effects of treatment on exploratory DMD-related biomarkers, BNP
Description
Absolute and percent (where applicable) change in Brain Natriuretic Peptide (BNP)
Time Frame
6 months plus 12 month extension
Title
To evaluate the effects of treatment on exploratory DMD-related biomarkers, BDNF
Description
Absolute and percent (where applicable) change in Brain-derived neurotrophic factor (BDNF)
Time Frame
6 months plus 12 month extension

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male subjects 16 years of age or older who provide informed consent and can follow up with protocol procedures. Parental or guardian consent is required for subjects at least 16 years of age but younger than 18 years of age. Documented diagnosis of Duchenne muscular dystrophy by genetic mutation analysis. Documented cardiomyopathy, as assessed by echocardiogram with EF >35% and <55% and fractional shortening of ≤ 28% at the time of screening. Subjects must be taking systemic glucocorticoids for at least six months prior to screening. Subjects taking mineralocorticoid receptor antagonists, must be taking the drug for at least three months prior to screening Non-ambulant and cared for by a trained caregiver Exclusion Criteria: Therapy with intravenous inotropic or vasoactive medications at the time of screening Planned or likelihood of major surgery in the 6 months after planned enrollment. Patient is using a left ventricular assist device (LVAD) or actively in the process of acquiring a LVAD. Estimated glomerular filtration rate (GFR) <50 mL/min, as calculated by the CKD-EPI Creatinine equation 2021 (https://www.kidney.org/professionals/kdoqi/gfr_calculator) Reproducible (+/- 10%) difference between screening and baseline, percent predicted FVC between 45 and 85, inclusive, using best of 3 efforts at each visit Patients with non-invasive ventilation, such as CPAP and BiPAP Patient is suffering from unstable systemic allergic reaction(s), connective tissue disease or autoimmune disorder(s), requiring active intervention History of cardiac tumor or current cardiac tumor Known moderate-to-severe aortic stenosis/insufficiency or severe mitral stenosis/regurgitation Current alcohol or drug abuse Known history of chronic viral hepatitis unless considered cured based on hepatitis C RNA negative results Hepatic dysfunction upon screening evidenced by bilirubin levels or gamma-GT levels above normal, deemed as clinically significant by the PI/Sub-I, and/or abnormal hematology (hematocrit <25%, WBC <3000/μl, platelets <100,000/μl), without a reversible, identifiable cause. Total bilirubin elevations > 2 times the upper reference range, consistent with Gilbert's Syndrome, may be enrolled if there is no other evidence of liver dysfunction Uncontrolled diabetes (HbA1c >9.0 percent) Inability to comply with protocol-related procedures, including required study visits Any condition or other reason that, in the opinion of the investigator or Medical Monitor, would render the subject unsuitable for the study Currently receiving or received within 90 days of enrollment (Day 1) an investigational treatment on another clinical study or expanded access protocol. This will include patients currently being treated or who have not completed follow-up to treatment with an investigational cell-based therapy within 6 months prior to enrollment and patients actively receiving an investigational therapy for cardiovascular repair/regeneration.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Richard L Franklin, MD, PhD
Phone
1-617-245-0289
Ext
101
Email
rfranklin@constanttherapeutics.com
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth Wagner, MS, MBA
Phone
1-617-245-0289
Ext
102
Email
ewagner@constanttherapeutics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard L Franklin, MD, PhD
Organizational Affiliation
Constant Therapeutics LLC
Official's Role
Study Chair
Facility Information:
Facility Name
Hadassah Medical Center
City
Jerusalem
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Talia Dor, MD
First Name & Middle Initial & Last Name & Degree
Talia Dor, MD
Facility Name
Sheba Medical Center
City
Ramat Gan
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amir Dori, MD, PhD
First Name & Middle Initial & Last Name & Degree
Amir Dori, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy

We'll reach out to this number within 24 hrs